REGEN BIOPHARMA, INC.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|
| Revenue | $110.0K | $100.0K | $192.0K | $0 | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Gross Margin | — | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | $1.1M | $671.1K | $282.3K | $23.9K | $8.4K |
| SG&A Expense | $822.1K | $1.7M | $1.3M | $523.9K | $262.9K |
| Operating Income | $-2.5M | $-3.0M | $-2.0M | $-706.4K | $-319.8K |
| Operating Margin | -2,282.6% | -2,957.0% | -1,030.9% | — | — |
| Interest Expense | $98.8K | $27.8K | $21.7K | $2.2K | $0 |
| Pretax Income | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — |
| Net Income | $-5.8M | $-7.8M | $-11.2M | $-756.4K | $-355.0K |
| Net Margin | -5,308.2% | -7,750.6% | -5,830.8% | — | — |
| EPS (Basic) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 23.76B | 21.48B | 14.82B | 8.69B | 9.55B |
| Shares Outstanding (Diluted) | 23.76B | 21.48B | 14.82B | 8.69B | 9.55B |
| Dividends Per Share | — | — | — | — | — |